Abstract 4697
Background
PAM50 (Prosigna®) identifies a gene-expression profile that categorises early breast cancer (BC) in intrinsic subtypes and gives prognostic estimation based on a 10 year-recurrence risk score (ROR). The purpose of this study was to evaluate the impact of PAM50's information on adjuvant treatment decisions.
Methods
Prospective collection of BC cases treated in a Cancer Centre in the last 10 months, in which PAM50 was used to define treatment strategy. Demographic, clinic and pathologic characteristics are described. Concordance between immunohistochemistry (IHC) and PAM50 subtypes were assessed as well as therapeutic decision changes according to risk stratification, using blind revision. Categorical variables were compared used chi-square test.
Results
Inclusion of 101 patients, median age of 52 years (34-79 years). Fifty-five patients (54.5%) were premenopausal, 71 (70.3%) had ductal carcinomas, 71 (70.3%) pT1c, 99 (98%) G2, 72 (71.3%) pN0, ER positive and HER2 negative. Eighty five(84.2%) had a PR expression above 20% and 63 (62.4%) had a Ki67≤15%. Overall discordance rate between BC subtypes by IHQ and PAM50 was 34%, (p < 0.001). By IHC, 51 (50.5%) were luminal A-like. Forty seven(92%) remained luminal A with PAM 50 [(low ROR: 28 (60%), intermediate:16 (34%), high:3 (6%)]. Four (8%) changed to luminal B [intermediate ROR:1 (25%), high:3 (75%)]. Of the 50 luminal B-like tumours (49.5%), 20 (40%) remained luminal B [intermediate ROR: 8 (40%); high:12 (60%)] and 30 (60%) changed to luminal A [low ROR:18 (60%), intermediate:12 (40%)]. Based on PAM50, adjuvant strategy was changed in 28 patients (28%), (p = 0.001): 15 (54%) changed from endocrine therapy (ET) only to chemotherapy (CT) also and 13 (46%) changed from CT and ET to ET only.
Conclusions
PAM50 availability results in 28% change in adjuvant plan with more cases of chemotherapy. The 34% discordance with classic IHC subgroups, especially in luminal B tumours, underlines the need for more accurate tests in this heterogeneous population to define the adequate adjuvant strategy. A longer follow up is important to evaluate the prognostic value of clinical decisions based on genetic signatures.
Clinical trial identification
Legal entity responsible for the study
Breast Department - IPO-Porto.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract